Biomarkers stratify disease phenotype and therapeutic response in inflammatory bowel disease

European Gastroenterology and Hepatology Review

Volumn 7, Issue 4, 2012, Pages 224-228

  Scherl, Ellen J ^a,b   Longman, Randy S ^b  

^a Clinical Medicine UWSMPH Marshfield Campus Marshfield Clinic   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Crohn's disease; Faecal biomarkers; Infliximab; Serological biomarkers; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CD RELATED BACTERIAL SEQUENCE 12 ANTIBODY; CERTOLIZUMAB PEGOL; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LOAD; CROHN DISEASE; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; FECES ANALYSIS; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; MICROBIOME; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 2 GENE; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PSEUDOMONAS FLUORESCENS; REMISSION; SACCHAROMYCES CEREVISIAE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; ULCERATIVE COLITIS;

EID: 84875259185     PISSN: 17583799     EISSN: 17583802     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB., Differing acute phase responses in Crohn's disease and ulcerative colitis, Gut, 1986;27(7):809-13.
2. Consigny Y, Modigliani R, Colombel JF, et al., A simple biological score for predicting low risk of short-term relapse in Crohn's disease, Inflamm Bowel Dis, 2006;12(7):551-7.
3. Louis E, Vermeire S, Rutgeerts P, et al., A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism, Scand J Gastroenterol, 2002;37(7):818-24.
4. Schreiber S, Rutgeerts P, Fedorak RN, et al., A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease, Gastroenterology, 2005;129(3):807-18.
5. Sandborn WJ, Feagan BG, Stoinov S, et al., Certolizumab pegol for the treatment of Crohn's disease, N Engl J Med, 2007;357(3):228-38.
6. Dubinsky M, What is the role of serological markers in IBD? Pediatric and adult data, Dig Dis, 2009;27(3):259-68.
7. Duerr RH, Targan SR, Landers CJ, et al., Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses, Gastroenterology, 1991;100(6):1590-6.
8. Seibold F, Brandwein S, Simpson S, et al., pANCA represents a cross-reactivity to enteric bacterial antigens, J Clin Immunol, 1998;18(2):153-60.
9. Cohavy O, Bruckner D, Gordon LK, et al., Colonic bacteria express an ulcerative colitis pANCA-related protein epitope, Infect Immun, 2000;68(3):1542-8.
10. Sendid B, Colombel JF, Jacquinot PM, et al., Specific antibody response to oligomannosidic epitopes in Crohn's disease, Clin Diagn Lab Immunol, 1996;3(2):219-26.
11. Quinton JF, Sendid B, Reumaux D, et al., Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role, Gut, 1998;42(6):788-91.
12. Landers CJ, Cohavy O, Misra R, et al., Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens, Gastroenterology, 2002;123(3):689-99.
13. Targan SR, Landers CJ, Yang H, et al., Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease, Gastroenterology, 2005;128(7):2020-8.
14. Peeters M, Joossens S, Vermeire S, et al., Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease, Am J Gastroenterol, 2001;96(3):730-4.
15. Sura S, Ahmed A, Cheifetz A, Moss A., Clinical Utility of Inflammatory Bowel Disease Serology Testing in Patients with Suspected Inflammatory Bowel Disease. Poster presented at: American College of Gastroenterology Annual Meeting, San Antonio; 15-20 October 2010.
16. Vasiliauskas EA, Kam LY, Karp LC, et al., Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics, Gut, 2000;47(4):487-96.
17. Forcione DG, Rosen MJ, Kisiel JB, Sands BE., Anti- Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease, Gut, 2004;53(8):1117-22.
18. Vasiliauskas EA, Plevy SE, Landers CJ, et al., Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup, Gastroenterology, 1996;110(6):1810-9.
19. Fleshner PR, Vasiliauskas EA, Kam LY, et al., High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis, Gut, 2001;49(5):671-7.
20. Mow WS, Vasiliauskas EA, Lin YC, et al., Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease, Gastroenterology, 2004;126(2):414-24.
21. Arnott ID, Landers CJ, Nimmo EJ, et al., Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype, Am J Gastroenterol, 2004;99(12):2376-84.
22. Shen B, Obusez E, Queener E., Evaluation of IBD serology in inflammatory and non-inflammatory disorders of the ileal pouch. Poster presented at: American College of Gastroenterology Annual Meeting, San Antonio, 15-20 October 2010.
23. Dotan I, Fishman S, Dgani Y, et al., Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease, Gastroenterology, 2006;131(2):366-78.
24. Ferrante M, Henckaerts L, Joossens M, et al., New serological markers in inflammatory bowel disease are associated with complicated disease behaviour, Gut, 2007;56(10):1394-403.
25. Taylor KD, Plevy SE, Yang H, et al., ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease, Gastroenterology, 2001;120(6):1347-55.
26. Esters N, Vermeire S, Joossens S, et al., Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease, Am J Gastroenterol, 2002;97(6):1458-62.
27. Ferrante M, Vermeire S, Katsanos KH, et al., Predictors of early response to infliximab in patients with ulcerative colitis, Inflamm Bowel Dis, 2007;13(2):123-8.
28. Martínez-Borra J, López-Larrea C, González S, et al., High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease, Am J Gastroenterol, 2002;97(9):2350-6.
29. van Deventer SJ., Transmembrane TNF-alpha induction of apoptosis and the efficacy of TNF-targeting therapies in Crohn's disease, Gastroenterology, 2001;121(5):1242-6.
30. Baert F, Noman M, Vermeire S, et al., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, 2003;348(7):601-8.
31. Sandborn WJ, Hanauer SB, Rutgeerts P, et al., Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial, Gut, 2007;56(9):1232-9.
32. Wang SL, Ohrmund L, Ling N, Singh S, Analysis of anti-drug antibodies (ADA) to adalimumab in patient serum using a novel homogeneous mobility shift assay. Poster presented at: American College of Gastroenterology Annual Meeting, San Antonio, 15-20 October 2010.
33. Wolbink GJ, Voskuyl AE, Lems WF, et al., Relationship between serum trough infliximab levels pretreatment C reactive, protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Ann Rheum Dis, 2005;64(5):704-7.
34. Ainsworth MA, Bendtzen K, Brynskov J., Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease, Am J Gastroenterol, 2008;103(4):944-8.
35. Afif W, Loftus EV Jr, Faubion WA, et al., Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease, Am J Gastroenterol, 2010;105(5):1133-9.
36. Maser EA, Villela R, Silverberg MS, Greenberg GR., Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Clin Gastroenterol Hepatol, 2006;4(10):1248-54.
37. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K., Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study, Inflamm Bowel Dis, 2005;11(6):589-96.
38. Nikolaus S, Raedler A, Kühbacker T, et al., Mechanisms in failure of infliximab for Crohn's disease, Lancet, 2000;356(9240):1475-9.
39. Schmidt C, Giese T, Hermann E, et al.,. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy, Inflamm Bowel Dis, 2007;13(1):65-70.
40. Olsen T, Goll R, Cui G, et al., TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis, Cytokine, 2009;46(2):222-7.
41. Arijs I, Li K, Toedter G, Quintens R, et al., Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis, Gut, 2009;58(12):1612-9.
42. Arijs I, Quintens R, Van Lommel L, et al., Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease, Inflamm Bowel Dis, 2010;16(12):2090-8.
43. Van Limbergen J, Wilson DC, Satsangi J., The genetics of Crohn's disease, Annu Rev Genomics Hum Genet, 2009;10: 89-116.
44. Hampe J, Cuthbert A, Croucher PJ, et al., Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations, Lancet, 2001;357(9272):1925-8.
45. Hugot JP, Chamaillard M, Zouali H, et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease, Nature, 2001;411(6837):599-603.
46. Ogura Y, Bonen DK, Inohara N, et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature, 2001;411(6837):603-6.
47. Cuthbert AP, Fisher SA, Mirza MM, et al., The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease, Gastroenterology, 2002;122(4):867-74.
48. Abreu MT, Taylor KD, Lin YC, et al., Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease, Gastroenterology, 2002;123(3):679-88.
49. Annese V, Lombardi G, Perri F, et al., Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease--an IG-IBD study, Am J Gastroenterol, 2005;100(1):84-92.
50. Ippoliti A, Devlin S, Mei L, et al., Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease, Inflamm Bowel Dis, 2010;16(8):1279-85.
51. Alvarez-Lobos M, Arostegui JI, Sans M, et al., Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence, Ann Surg, 2005;242(5):693-700.
52. Weersma RK, Stokkers PC, Cleynen I, et al., Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch- Belgian cohort, Am J Gastroenterol, 2009;104(3):630-8.
53. Franke A, Balschun T, Karlsen TH, et al., Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40(11):1319-23.
54. UK IBD Genetics Consortium, Barrett JC, Lee JC, Lees CW, et al., Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region, Nat Genet, 2009;41(12):1330-4.
55. Dubinsky MC, Mei L, Friedman M, et al., Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease, Inflamm Bowel Dis, 2010;16(8):1357-66.
56. Limburg PJ, Ahlquist DA, Sandborn WJ, et al., Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy, Am J Gastroenterol, 2000;95(10):2831-7.
57. Schröder O, Naumann M, Shastri Y, Povse N, et al., Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin, Aliment Pharmacol Ther, 2007;26(7):1035-42.
58. D'Incà R, Dal Pont E, Di Leo V, et al., Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease, Int J Colorectal Dis, 2007;22(4):429-37.
59. Langhorst J, Elsenbruch S, Koelzer J, et al., Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices, Am J Gastroenterol, 2008;103(1):162-9.
60. Schoepfer AM, Beglinger C, Straumann A, et al., Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI, Am J Gastroenterol, 2010;105(1):162-9.
61. Schoepfer AM, Beglinger C, Straumann A, et al., Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes, Inflamm Bowel Dis, 2009;15(12):1851-8.
62. Gisbert JP, Bermejo F, Pérez-Calle JL, et al., Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflamm Bowel Dis, 2009;15(8):1190-8.
63. D'Incà R, Dal Pont E, Di Leo V, et al., Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol, 2008;103(8):2007-14.
64. Sipponen T, Savilahti E, Kärkkäinen P, et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease, Inflamm Bowel Dis, 2008;14(10):1392-8.
65. Caccaro R, D'Incá R, Sturniolo GC., Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease, Expert Rev Clin Immunol, 2010;6(4):551-8.
66. Turnbaugh PJ, Hamady M, Yatsunenko T, et al., A core gut microbiome in obese and lean twins, Nature, 2009;457(7228):480-4.
67. Frank DN, St Amand AL, Feldman RA, et al., Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc Natl Acad Sci U S A, 2007;104(34):13780-5.
68. Baumgart M, Dogan B, Rishniw M, et al., Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum, ISME J, 2007;1(5):403-18.
69. Sokol H, Pigneur B, Watterlot L, et al., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc Natl Acad Sci U S A, 2008;105(43):16731-6.
70. Jia W, Whitehead RN, Griffiths L, et al., Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett, 2010;310(2):138-44.
71. Willing BP, Dicksved J, Halfvarson J, et al., A Pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes, Gastroenterology, 2010;139(6):1844-54
72. Swidsinski A, Loening-Baucke V, Bengmark S, et al., Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis, Inflamm Bowel Dis, 2007;13(1):51-6.
73. Maslowski KM, Vieira AT, Ng A., et al., Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43, Nature, 2009;461(7268):1282-6.
74. Wong JM, de Souza R, Kendall CW, et al., Colonic health: fermentation and short chain fatty acids, J Clin Gastroenterol, 2006;40(3):235-43.
75. Atarashi K, Nishimura J, Shima T, et al., ATP drives lamina propria T(H)17 cell differentiation, Nature, 2008;455(7214):808-12.
76. Jansson J, Willing B, Lucio M, et al., Metabolomics reveals metabolic biomarkers of Crohn's disease, PLoS ONE, 2009;4(7):e6386.